DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Notice of meeting.

SUMMARY: This is a notice to inform the public of an upcoming meeting of the Secretary’s Advisory Committee on Animal Health. The meeting is being organized by the Animal and Plant Health Inspection Service to discuss matters of animal health.

DATES: The meeting will be held on April 28 and 29, 2015, from 9 a.m. to 5 p.m. each day.

ADDRESSES: The meeting will be held at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

FOR FURTHER INFORMATION CONTACT: Mrs. R.J. Cabrera, Designated Federal Officer, VS, APHIS, 4700 River Road Unit 34, Riverdale, MD 20737; phone (301) 851–3478, email SACAH.Management@aphis.usda.gov.

SUPPLEMENTARY INFORMATION: The Secretary’s Advisory Committee on Animal Health (the Committee) advises the Secretary of Agriculture on matters of animal health, including means to prevent, conduct surveillance on, monitor, control, or eradicate animal diseases of national importance. In doing so, the Committee will consider public health, conservation of natural resources, and the stability of livestock economies.

Tentative topics for discussion at the meeting include:

- Follow-on discussion of antimicrobial resistance, mitigations, and the U.S. Department of Agriculture (USDA) action plan,
- Comprehensive discussion on porcine epidemic diarrhea,
- Follow-on discussion on foot-and-mouth disease,
- USDA draft framework for emerging diseases,
- Proposed national list of reportable animal diseases,
- Avian influenza, and
- Bovine tuberculosis program—understanding the disease.

A final agenda will be posted on the Committee Web site by April 13, 2015.

Those wishing to attend the meeting in person must complete a brief registration form by clicking on the “SACAH Meeting Sign-Up” button on the Committee’s Web site (http://www.aphis.usda.gov/animalhealth/sacah). Members of the public may also join the meeting via teleconference in “listen-only” mode. Participants who wish to listen in on the teleconference may do so by dialing 1–888–469–3079 and then entering the public passcode, 2061888#.

Due to time constraints, members of the public will not have an opportunity to participate in the Committee’s discussions. However, questions and written statements for the Committee’s consideration may be submitted up to 5 working days before the meeting. They may be sent to SACAH.Management@aphis.usda.gov or mailed to the person listed on the notice under FOR FURTHER INFORMATION CONTACT. Statements filed with the Committee should specify that they pertain to the April 2015 Committee meeting.

This notice of meeting is given pursuant to section 10 of the Federal Advisory Committee Act (5 U.S.C. App. 2).

Done in Washington, DC, this 8th day of April 2015.

Kevin Shea,
Administrator, Animal and Plant Health Inspection Service.

DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service

[DOCKET NO. APHIS–2015–0003]

Availability of an Environmental Assessment for Field Testing a Marek’s Disease Vaccine, Serotype 1, Live Virus

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Notice of availability.

SUMMARY: We are advising the public that the Animal and Plant Health Inspection Service has prepared an environmental assessment concerning authorization to ship for the purpose of field testing, and then to field test, an unlicensed Marek’s disease vaccine, serotype 1, live virus. The environmental assessment, which is based on a risk analysis prepared to assess the risks associated with the field testing of this vaccine, examines the potential effects that field testing this veterinary vaccine could have on the quality of the human environment.

Based on the risk analysis and other relevant data, we have reached a preliminary determination that field testing this veterinary vaccine will not have a significant impact on the quality of the human environment, and that an environmental impact statement need not be prepared. We intend to authorize shipment of this vaccine for field testing following the close of the comment period for this notice unless new substantial issues bearing on the effects of this action are brought to our attention. We also intend to issue a U.S. Veterinary Biological Product license for this vaccine, provided the field test data support the conclusions of the environmental assessment and the issuance of a finding of no significant impact and the product meets all other requirements for licensing.

DATES: We will consider all comments that we receive on or before May 14, 2015.

ADDRESSES: You may submit comments by either of the following methods:

- Postal Mail/Commercial Delivery: Send your comment to Docket No. APHIS–2015–0003, Regulatory Analysis and Development, PPD, APHIS, Station 3A–03.8, 4700 River Road Unit 118, Riverdale, MD 20737–1238.

Supporting documents and any comments we receive on this docket may be viewed at http://
DEPARTMENT OF COMMERCE
Submission for OMB Review; Comment Request

The Department of Commerce will submit to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35).

Agency: U.S. Census Bureau.
Title: Comparing Health Insurance Measurement Error (CHIME).
OMB Control Number: 0607–XXXX.
Form Number(s): No forms; respondent information collected by telephone interview.
Type of Request: Regular submission.
Number of Respondents: 5,000 Households.
Average Hours Per Response: 13 minutes.
Burden Hours: 3,028 hours.

Needs and Uses: The goal of the study is to assess measurement error in health coverage estimates that is ascribable to the questionnaire across the CPS and ACS health insurance modules using administrative records as a truth source. Both “absolute” reporting accuracy (the survey report compared to the administrative record data) and “relative” reporting accuracy (comparing absolute accuracy across questionnaire treatments) will be evaluated. The analysis will be used to understand the magnitude, direction and patterns of misreporting for three main purposes: (1) To provide Census program staff with empirical data to develop and refine edits and/or include research notes for data users so they can make their own adjustments for misreporting; (2) to equip the wider research community with information that could serve as a guide for deciding which among the various surveys best suits their needs; and (3) to contribute to the general survey microdata research literature on measurement error.
Analysis will also inform reporting accuracy of health coverage related to the Affordable Care Act (ACA).
Specifically, for coverage that is known to be obtained from the marketplace, we will explore whether respondents report that coverage, the source they cite (direct-purchase, government, etc.), and the accuracy with which they answer a question on subsidized premiums.

The attenuated vaccine is intended for use in healthy day-old chickens, as an aid in the prevention of Marek’s disease caused by very virulent Marek’s disease virus.

The EA has been prepared in accordance with: (1) The National Environmental Policy Act of 1969 (NEPA), as amended (42 U.S.C. 4321 et seq.), (2) regulations of the Council on Environmental Quality for implementing the procedural provisions of NEPA (40 CFR parts 1500–1508), (3) USDA regulations implementing NEPA (7 CFR part 1b), and (4) APHIS’ NEPA Implementing Procedures (7 CFR part 372).

Unless substantial issues with adverse environmental impacts are raised in response to this notice, APHIS intends to issue a finding of no significant impact (FONSI) based on the EA and authorize shipment of the above product for the initiation of field tests following the close of the comment period for this notice.

Because the issues raised by field testing and by issuance of a license are identical, APHIS has concluded that the EA that is generated for field testing would also be applicable to the proposed licensing action. Provided that the field test data support the conclusions of the original EA and the issuance of a FONSI, APHIS does not intend to issue a separate EA and FONSI to support the issuance of the product license, and would determine that an environmental impact statement need not be prepared. APHIS intends to issue a veterinary biological product license for this vaccine following completion of the field test provided no adverse impacts on the human environment are identified and provided the product meets all other requirements for licensing.


Done in Washington, DC, this 8th day of April 2015.
Kevin Shea,
Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 2015–08604 Filed 4–13–15; 8:45 am]
BILLING CODE 3410–34–P

www.regulations.gov/
#docketDetail Docket: APHIS–2015–0003 or in our reading room, which is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 799–7039 before coming.

FOR FURTHER INFORMATION CONTACT: Dr. Donna Malloy, Operational Support Section, Center for Veterinary Biologics, Policy, Evaluation, and Licensing, VS, APHIS, 4700 River Road Unit 148, Riverdale, MD 20737–1231; phone (301) 851–3426, fax (301) 734–4314.

For information regarding the environmental assessment or the risk analysis, or to request a copy of the environmental assessment (as well as the risk analysis with confidential business information removed), contact Dr. Patricia L. Foley, Risk Manager, Center for Veterinary Biologics, Policy, Evaluation, and Licensing, VS, APHIS, 1920 Dayton Avenue, P.O. Box 844, Ames, IA 50010; phone (515) 337–6100, fax (515) 337–6120.

SUPPLEMENTARY INFORMATION:

Under the Virus-Serum-Toxin Act (21 U.S.C. 151 et seq.), a veterinary biological product must be shown to be pure, safe, potent, and efficacious before it meets all other requirements for licensing.

The above-mentioned product is a veterinary biological product: a live Marek’s Disease vaccine, Serotype 1, Live Virus.

Possible Field Test Locations:
Arkansas, Georgia, Kentucky, North Carolina, Tennessee, and Texas.

The above-mentioned product is a live Marek’s Disease serotype 1 vaccine virus containing the long terminal repeat of the reticuloendotheliosis virus.